166 related articles for article (PubMed ID: 36878410)
1. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C; Hennart B; Leroy AG; Corvec S; Boutoille D; Senneville É; Sotto A; Illes G; Chavanet P; Dubée V; Bleibtreu A; De Carné MC; Talarmin JP; Revest M; Castan B; Bellouard R; Dailly É; Allorge D; Dinh A; Le Turnier P; Gregoire M;
J Antimicrob Chemother; 2023 Dec; 78(12):2919-2925. PubMed ID: 37864551
[TBL] [Abstract][Full Text] [Related]
4. Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections.
Cojutti PG; Gatti M; Punt N; Douša J; Zamparini E; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2024 Jan; 63(1):107038. PubMed ID: 37981075
[TBL] [Abstract][Full Text] [Related]
5. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients.
Carrothers TJ; Lagraauw HM; Lindbom L; Riccobene TA
Pediatr Infect Dis J; 2023 Feb; 42(2):99-105. PubMed ID: 36638392
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.
Cojutti PG; Rinaldi M; Zamparini E; Rossi N; Tedeschi S; Conti M; Pea F; Viale P
Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33649108
[No Abstract] [Full Text] [Related]
8. Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections.
Gallerani A; Gatti M; Bedini A; Casolari S; Orlando G; Puzzolante C; Franceschini E; Menozzi M; Santoro A; Barp N; Volpi S; Soffritti A; Pea F; Mussini C; Meschiari M
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998841
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
11. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections.
Cattaneo D; Fusi M; Galli L; Genovese C; Giorgi R; Matone M; Merli S; Colaneri M; Gori A
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0002324. PubMed ID: 38385700
[TBL] [Abstract][Full Text] [Related]
12.
Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
[No Abstract] [Full Text] [Related]
13. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
15. Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections.
Stroffolini G; De Nicolò A; Gaviraghi A; Mula J; Cariti G; Scabini S; Manca A; Cusato J; Corcione S; Bonora S; Di Perri G; De Rosa FG; D'Avolio A
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145630
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
[TBL] [Abstract][Full Text] [Related]
19. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
[TBL] [Abstract][Full Text] [Related]
20. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
